Maven CDMS, JNPMEDI's clinical solution, acquires the first WHODrug B3/C3 in Korea at the same time.

Source: who-umc.org

JNPMEDI's clinical trial data management solution, "Maven CDMS (Clinical Data Management System), has been registered as a software approved by WHODrug Global.

WHODrug Global is an internationally used drug information dictionary. Information is collected from about 150 countries around the world and is used for consistency and accuracy of terms when entering information on combination treatments or adverse drug reactions.

Drugs or ingredients registered by the Food and Drug Administration (FDA) and the European Medicines Agency (EMA) are also regularly updated.

Using standard data from WHODrug Global makes it easier to identify drug problems that occur during clinical trials and drug monitoring activities and has the advantage of developing drugs more safely. This is because WHODrug can be used to enter drug information to conduct more efficient analysis, while data submission to drug regulators is accelerated.

Drug regulators around the world value the submission of drug information in a standardized format, and there is also a growing awareness that common dictionaries and accurate terms should be used for clinical trials and drug monitoring. The FDA has mandated the use of WHODrug Global in clinical trials since 2019.

For this reason, the application of WHODrug Global is becoming essential for software that handles drug information.

As of January 2022, there were 44 software approved by WHODrug Global, of which "Maven CDMS" is the only domestic product that satisfies both B3 and C3 registration formats.

More information on approval can be found on the WHODrug official website (who-umc.org).